Core Viewpoint - The CEO of Eli Lilly announced the company's focus on research for Alzheimer's disease prevention and other brain disorders [1] Group 1 - Eli Lilly is actively engaging in research aimed at preventing Alzheimer's disease [1] - The company is expanding its research efforts to include other brain-related diseases [1]

Core Viewpoint - The CEO of Eli Lilly emphasizes the importance of not raising drug prices [1] Group 1 - The company is committed to maintaining affordable drug prices to ensure accessibility for patients [1]

【隔夜行情】 •周四（2025年4月18日），A股三大股指涨跌互现，截至收盘，上证综指涨0.13%，报3280.34点；科创 50指数涨0.23%，报1016.81点；深证成指跌0.16%，报9759.05点；创业板指涨0.09%，报1908.78点。沪 深两市成交总额9995亿元，较前一交易日的11119亿元减少1124亿元。 •周四（2025年4月18日），港股三大指数强势反弹，恒科指一度涨超2%。截止收盘，恒生指数涨1.61% 或338.16点，报21395.14点，全日成交额1924.11亿港元；恒生国企指数涨1.52%，报7897.44点；恒生科 技指数涨1.9%，报4887.37点。 【重要新闻】 【六部门印发《促进和规范金融业数据跨境流动合规指南》 进一步明确数据出境的具体情形以及可跨 境流动的数据项清单】4月17日，央行等六部门联合印发《促进和规范金融业数据跨境流动合规指 南》，旨在促进中外资金融机构金融业数据跨境流动更加高效、规范，进一步明确数据出境的具体情形 以及可跨境流动的数据项清单，便利数据跨境流动。《指南》要求金融机构采取必要的数据安全保护管 理和技术措施切实保障数据安全。下一步，中 ...

Eli Lilly & Co. LLY shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market projected to more than triple in size by 2030. The stock surged, closing the day up 14.36% to $839.96, marking its best performance since June 2000.In a Thursday note, Goldman Sachs analyst Asad Haider, CFA said Eli Lilly's first Phase 3 trial of orforglipron — a once-daily oral treatment for type 2 diabetes and ...

Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled positive momentum in trade negotiations.Speaking ahead of a scheduled meeting with Italian Prime Minister Giorgia Meloni, Trump expressed strong confidence in reaching a trade agreement with the European Union. He also hinted at progress with China, stating, "We will make a good deal with China." Meanwhile, U.S. Treasury Secretary Scott Bessent noted that trade talks with Japan are mov ...

Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding.It's Thursday morning, 11:50 a.m. ET -- and Eli Lilly (LLY 16.30%) stock is off to the races!This morning, the Indianapolis-based pharmaceutical giant announced that its new GLP-1 weight loss pill, orforglipron, has "demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful [ACHIEVE-1] Phase 3 trial."Lilly shares are up 14.2% in response to the ...

Core Viewpoint - Eli Lilly's experimental oral drug orforglipron demonstrated significant weight loss in Type 2 diabetes patients, leading to a 15% surge in its stock price, indicating strong market potential for oral GLP-1 receptor agonists [1][5][12]. Company Summary - Eli Lilly's orforglipron trial results showed an average weight loss of 16 pounds (7.9% of body weight) over 26 weeks, outperforming Novo Nordisk's Ozempic, which resulted in a 6% weight loss at its highest dose [1][2][3]. - The drug also achieved a 1.3% average reduction in blood sugar levels, slightly below Ozempic's 2.1% reduction, but overall efficacy in weight loss and diabetes management has been positively received [3][12]. - If approved, orforglipron could provide a convenient oral alternative to injectable medications, addressing a significant barrier to adoption of current GLP-1 therapies [11][12][14]. Industry Summary - The demand for GLP-1 receptor agonists has surged due to rising global obesity rates and a growing preference for pharmaceutical weight management solutions [9]. - Novo Nordisk's shares fell by 3.9% amid concerns that orforglipron could challenge its market dominance with Ozempic and Wegovy, which are currently only available in injectable form [4][14]. - The oral GLP-1 market is becoming increasingly competitive, with Eli Lilly's orforglipron trial being one of several studies aimed at expanding the drug's potential applications, including obesity and sleep apnea [12][14].

Eli Lilly & Co (NYSE:LLY) stock is headed for its best day since August 2023, last seen up 13.4% at $838.48 at last check, after the pharmaceutical giant reported positive results for a phase 3 trial of its weight-loss drug, orforglipron. The experimental pill resulted in weight loss of nearly 8% at the highest dose, and lowered blood sugar in patients with type 2 diabetes. Today's pop helped Eli Lilly stock fully recover from its early April bear gap, and has it back in positive territory for 2025. LLY was ...

Core Points - Eli Lilly and Company will announce its first-quarter 2025 financial results on May 1, 2025, and will hold a conference call to discuss the performance [1] - The conference call is scheduled to begin at 10 a.m. Eastern time, and a live webcast will be available on Lilly's website [2] - Lilly has been a pioneer in medical discoveries for nearly 150 years, focusing on various health challenges including diabetes care, obesity treatment, Alzheimer's disease, immune system disorders, and cancer management [3]

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...